CLINICAL TRIALS PROFILE FOR PEVONEDISTAT
✉ Email this page to a colleague
Clinical Trials for Pevonedistat
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01814826 ↗ | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in treatment naive participants with AML who were 60 years of age or older. |
| NCT01862328 ↗ | Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | Completed | Millennium Pharmaceuticals, Inc. | Phase 1 | The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel and carboplatin, and gemcitabine in participants with solid tumors. |
| NCT02610777 ↗ | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast AML. |
| NCT02782468 ↗ | A Study of Pevonedistat in Adult East Asian Participants | Active, not recruiting | Millennium Pharmaceuticals, Inc. | Phase 1 | The purpose of this study is to evaluate the safety and tolerability of pevonedistat administered as a single agent and in combination with azacitidine in adult east Asian participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). |
| NCT03009240 ↗ | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | This phase I trial studies the side effects and best dose of pevonedistat when given together with decitabine in treating patients with high risk acute myeloid leukemia. Pevonedistat and decitabine may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. |
| NCT03009240 ↗ | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | Active, not recruiting | City of Hope Medical Center | Phase 1 | This phase I trial studies the side effects and best dose of pevonedistat when given together with decitabine in treating patients with high risk acute myeloid leukemia. Pevonedistat and decitabine may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. |
| NCT03013998 ↗ | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Recruiting | Beat AML, LLC | Phase 1/Phase 2 | This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Pevonedistat
Condition Name
Clinical Trial Locations for Pevonedistat
Trials by Country
Clinical Trial Progress for Pevonedistat
Clinical Trial Phase
Clinical Trial Sponsors for Pevonedistat
Sponsor Name
